{"id":5514,"date":"2015-08-10T05:47:29","date_gmt":"2015-08-10T05:47:29","guid":{"rendered":"http:\/\/revoscience.com\/en\/?p=5514"},"modified":"2015-08-10T05:47:29","modified_gmt":"2015-08-10T05:47:29","slug":"idrc-welcomes-early-ebola-vaccine-trial-results","status":"publish","type":"post","link":"https:\/\/www.revoscience.com\/en\/idrc-welcomes-early-ebola-vaccine-trial-results\/","title":{"rendered":"IDRC welcomes early Ebola vaccine trial results"},"content":{"rendered":"<figure id=\"attachment_5515\" aria-describedby=\"caption-attachment-5515\" style=\"width: 300px\" class=\"wp-caption alignright\"><a href=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-5515 size-medium\" src=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea-300x200.jpg\" alt=\"Ebola vaccine trial in Guinea\" width=\"300\" height=\"200\" title=\"\" srcset=\"https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea-300x200.jpg 300w, https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea-1024x683.jpg 1024w, https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg 1114w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><figcaption id=\"caption-attachment-5515\" class=\"wp-caption-text\">MSF | YANN LIBESSART<\/figcaption><\/figure>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">International Development Research Centre (IDRC) is proud to be a key partner in the clinical trial of a \u201cgame-changing\u201d candidate Ebola vaccine, a critical part of the global effort to ensure the world is better prepared for the next outbreak.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">If preliminary results of the vaccine trial underway in Guinea are confirmed, it &#8220;is going to be a game-changer,&#8221; said Dr Margaret Chan, Director-General of the World Health Organization. Interim analysis of the clinical trial, published in The Lancet medical journal, indicates a 100% efficacy rate. Further work and more conclusive evidence is needed, and the trial continues.<\/span><br style=\"color: #000000;\" \/><br style=\"color: #000000;\" \/><span style=\"color: #000000;\">&#8220;This is an extremely promising development,&#8221; Dr Chan said. &#8220;The credit goes to the Guinean Government, the people living in the communities, and our partners in this project. An effective vaccine will be another very important tool for both current and future Ebola outbreaks.&#8221;<\/span><br style=\"color: #000000;\" \/><br style=\"color: #000000;\" \/><span style=\"color: #000000;\">IDRC manages the Canadian partnership that is collaborating on the WHO-coordinated trial of the VSV-EBOV vaccine, which was originally developed in Canada. In March 2015, IDRC, the Canadian Institutes of Health Research, Foreign Affairs, Trade and Development Canada, and the Public Health Agency of Canada announced their joint support for the effort to test a preventive Ebola vaccine in Guinea, one of the three most-affected West African countries.<\/span><br style=\"color: #000000;\" \/><br style=\"color: #000000;\" \/><span style=\"color: #000000;\">The Canadian partnership has supported monitoring and safety assurance of the clinical trial, helped build the capacity of West African researchers conducting the work on the ground, and is supporting the peer review of trial results by Canadian scientists.\u00a0<\/span><br style=\"color: #000000;\" \/><br style=\"color: #000000;\" \/><span style=\"color: #000000;\">Almost 28,000 cases of Ebola have been reported in the worst-ever outbreak of the deadly virus, mostly in Guinea, Liberia, and Sierra Leone. Of those, more than 11,000 people have died.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>International Development Research Centre (IDRC) is proud to be a key partner in the clinical trial of a \u201cgame-changing\u201d candidate Ebola vaccine, a critical part of the global effort to ensure the world is better prepared for the next outbreak. If preliminary results of the vaccine trial underway in Guinea are confirmed, it &#8220;is going [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5515,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,17],"tags":[],"class_list":["post-5514","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicine","category-research"],"featured_image_urls":{"full":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",1114,744,false],"thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea-150x150.jpg",150,150,true],"medium":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea-300x200.jpg",300,200,true],"medium_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",750,501,false],"large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea-1024x683.jpg",750,500,true],"1536x1536":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",1114,744,false],"2048x2048":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",1114,744,false],"ultp_layout_landscape_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",1114,744,false],"ultp_layout_landscape":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",853,570,false],"ultp_layout_portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",600,401,false],"ultp_layout_square":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",600,401,false],"newspaper-x-single-post":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",734,490,false],"newspaper-x-recent-post-big":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",539,360,false],"newspaper-x-recent-post-list-image":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",95,63,false],"web-stories-poster-portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",640,427,false],"web-stories-publisher-logo":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",96,64,false],"web-stories-thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2015\/08\/MSF-Yann-Libessart-Ebola-trial-Guinea.jpg",150,100,false]},"author_info":{"info":["Amrita Tuladhar"]},"category_info":"<a href=\"https:\/\/www.revoscience.com\/en\/category\/health\/medicine\/\" rel=\"category tag\">Medicine<\/a> <a href=\"https:\/\/www.revoscience.com\/en\/category\/news\/research\/\" rel=\"category tag\">Research<\/a>","tag_info":"Research","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/5514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/comments?post=5514"}],"version-history":[{"count":0,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/5514\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media\/5515"}],"wp:attachment":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media?parent=5514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/categories?post=5514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/tags?post=5514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}